News and Announcements
Novogen Annual Cost Savings Identified of$1.8M, Allowing for Greater Focus on R&D Investment
- Published August 18, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Novogen Ltd (ASX:NRT) an Australian oncology drug development company, have recently provided an update on the company’s business operations.
KEY TAKEAWAWAYS:
- Board and management have reviewed all business operations following the appointment of a new Chairman during June 2017.
- Approximately $1.8 million of annual cost savings identified, allowing greater focus on R&D investment.
- Shareholder feedback, depository holders instructed not to exercise “unvoted ADR proxies at future general meetings.
- The company has confirmed compliance with NASDAQ listing rules following revision of ADR consolidation ratio.
Novogen Chairman, Ian Ross, commented: “recent efforts have significantly improved the efficiency of Novogen as a business, and will allow us to better devote our resources to delivering on the substantial value that resides in our pipelined.”
“The company has taken on board and listened carefully to the feedback of shareholders, and has shown its commitment to delivering shareholder value in accordance with the best principles of corporate governance.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
